Triamcinolone acetonide is a long-acting glucocorticoid with multiple pharmacological effects including anti-inflammatory, anti-allergic and immunosuppressive activities. It is available in a wide range of formulations for clinical use, including oral, injectable, topical and ophthalmic preparations. Indications and administration routes vary greatly among different formulations. Dosage control directly determines therapeutic efficacy and medication safety: excessive administration may lead to adverse reactions such as hormonal disturbance, local tissue atrophy and aggravated infection, whereas insufficient dosage fails to achieve therapeutic outcomes. In accordance with clinical medication guidelines, this article elaborates on the dosage requirements for each formulation of triamcinolone acetonide in detail.
I. Standard Routine Dosage by Formulation
(I) Oral Preparations
Oral triamcinolone acetonide is mainly indicated for systemic allergic disorders and autoimmune diseases. The routine initial adult dose is 4 mg per administration, administered 2 to 4 times daily. The dose is tapered gradually after disease stabilization, with a maintenance dose of 1–4 mg per dose given 1 to 2 times daily. Treatment shall follow the principle of low-dose maintenance and slow dose reduction to prevent disease rebound caused by abrupt discontinuation.
Pediatric dosing is calculated strictly based on body weight, with a conventional daily dose of 0.8–2 mg/kg divided into 3 to 4 administrations. Dosage may be adjusted appropriately according to age and disease severity. Long-term administration at excessive doses is prohibited.
(II) Injectable Preparations
Injectable formulations are widely used clinically via three administration routes: intramuscular injection, intra-articular injection and intralesional injection for skin lesions, with substantial inter-route dosage differences. For adult intramuscular injection, the standard single dose ranges from 20 to 80 mg once weekly, with a recommended initial dose of 60 mg titrated between 40 and 80 mg according to disease control response. A 20 mg single dose is effective for mild conditions. Injection sites shall be rotated to prevent local tissue injury.
Intra-articular and bursal injections are indicated for localized inflammation such as arthritis and synovitis, at a single dose of 2.5–5 mg adjusted according to lesion size and inflammatory severity. For intralesional injection in dermatological lesions, 0.2–0.3 mg is administered per lesion. The total daily dose shall not exceed 30 mg, and the maximum weekly total dose shall not exceed 75 mg. Injections are administered once every 3 to 4 weeks; frequent injections are contraindicated.
(III) Topical and Ophthalmic Preparations
Ointments and creams are used for eczema, dermatitis, pruritus and other skin disorders, applied thinly to affected areas 2 to 3 times daily with gentle massage to facilitate percutaneous absorption. Large-area and long-term thick application is forbidden to prevent systemic side effects from percutaneous drug absorption. Aerosols are used for inflammation of the respiratory tract, skin and mucous membranes, administered 3 to 4 times daily. Ophthalmic eye drops are prescribed for ocular inflammation, instilled in small amounts 1 to 4 times daily with strict control of local administration frequency.
II. Dosage Adjustment for Special Populations
Patients in special populations have compromised metabolic capacity and poor tolerance to glucocorticoids, necessitating rigorous dose reduction. Elderly patients experience physiological declines in hepatic and renal function leading to slower drug metabolism; their dosage shall be halved relative to the standard adult dose with shortened treatment duration. Children and adolescents are in a period of growth and development, so only short-term low-dose therapy is permitted. Long-term systemic administration is prohibited to avoid impaired bone development and endocrine dysfunction.
Triamcinolone acetonide shall be used with caution in pregnant and lactating women, only administered at the minimum effective dose when medically necessary. In patients with hepatic or renal insufficiency, impaired drug excretion may cause drug accumulation and toxicity; dosage shall be appropriately decreased and dosing intervals prolonged according to the degree of organ injury.
III. Core Dosing Principles and Contraindications
Medication with triamcinolone acetonide shall strictly adhere to three core principles: individualized therapy, minimum effective dose and short treatment course. No formulation shall be used at excessive doses or for prolonged durations. Frequent multi-site injection is prohibited for injectable forms, and long-term large-area topical application shall be avoided for external preparations. Dosage shall be dynamically adjusted during treatment based on disease progression; dose tapering or timely discontinuation is required upon symptom relief, and long-term maintenance therapy is generally unnecessary.
Strict upper dosage limits must be observed: the weekly total dose for intralesional injection shall not exceed 75 mg, and weekly intramuscular injection shall not exceed 80 mg. Large-scale full-body application of topical preparations is forbidden. Triamcinolone acetonide is contraindicated in patients with hypersensitivity to triamcinolone acetonide or uncontrolled severe infections, to prevent disease exacerbation and severe adverse reactions.
IV. Conclusion
Dosage administration of triamcinolone acetonide is highly formulation-specific and individualized, with distinct dosing criteria for systemic administration, local administration and special populations. In clinical and routine medication practice, clinicians shall strictly differentiate formulations, comply with standardized dosing regimens, and tailor treatment plans according to individual conditions and physical status. Arbitrary dose escalation and long-term medication must be avoided. This strategy ensures therapeutic efficacy while minimizing glucocorticoid-related adverse reactions, achieving safe, rational and appropriate pharmacotherapy.
